CHAD Therapeutics Wins FDA Approval for Device

CHAD Therapeutics Inc. of Chatsworth announced clearance by the Food and Drug Administration to market its new Oxymatic 411 electronic oxygen conserver.

CHAD produces and distributes oxygen conserving devices and oxygen systems used by pulmonary patients who need supplemental oxygen.